New 80M-euro GMP drug plant for Russia

18 June 2006

A new pharmaceuticals production facility is under construction in the Russian Lipetsk region at Terbuny, according to the Interfax news agency. Total investment in the center, including a 10,000 square metre is quoted at in excess of 80.0 million euros ($103.5 million).

Financing in the plant, which will operate to Good Manufacturing Practice standards and is due to be completed by April 2008, has been arranged by the Russian health charity "Zdrovye" and several private firms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight